Redwood Pharma AB

REDW

SE0021512134

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 10:02:14 2024-05-31 am EDT			5-day change	1st Jan Change
0.772 ^SEK	-3.74%		-4.93%	-83.57%

May. 08	Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	CI
May. 07	Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	CI

Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2021

May 11, 2021 at 09:50 am EDT

Redwood Pharma AB announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was SEK 3.934 million compared to SEK 4.431 million a year ago. Net loss was SEK 4.294 million compared to SEK 4.431 million a year ago.

Latest news about Redwood Pharma AB

Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	May. 08	CI
Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	May. 07	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Redwood Pharma AB Presents Positive Results from Clinical Study with RP501 Against Dry Eye	23-05-31	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Redwood Pharma AB Completes Recruitment for Clinical Trial with RP501 for Dry Eye	23-03-17	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Redwood Pharma to Scale-up Production for Upcoming Commercialization of Eye Dry Treatment	23-01-24	MT
Redwood Pharma AB Completes Further Preparations for the Scale-Up of Production of the Company's Medical Technology Product RP501	23-01-24	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Redwood Pharma AB Announces First Patient Has Started Redwood Pharma's Rp501 Treatment for Dry Eye	22-05-05	CI
Redwood Pharma Obtains Regulatory Approval To Start Trial In Austria for Dry Eye Disease Treatment	22-03-28	MT
Redwood Pharma Receives Approval from Austrian Federal Office for Safety in Health Care to Initiate Clinical Trial of RP501	22-03-28	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-16	CI
Redwood Pharma Receives Approval from an Austrian Ethics Committee for Start of A Clinical Trial of RP501	22-02-07	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-16	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-27	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-11	CI
Redwood Pharma AB Announces That Phase II Results Published in Medical Journal and Redwood Pharma to Present Poster At Medical Meeting	21-03-22	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2020	21-02-17	CI

Chart Redwood Pharma AB

Duration

Period

More charts

Company Profile

Redwood Pharma AB is a Sweden-based company, which is primarily focused on pharmaceutical industry. The Company develops IntelliGel, a patented hydrogel drug delivery platform technology. IntelliGel is a patented supramolecular smart drug delivery system with an ability to dissolve water-insoluble and sparingly soluble drugs, or disperse, suspend and stabilize otherwise insoluble drugs. It is an odor-free, clear and transparent hydrogel with low solid content, and forms an invisible patch when applied to a surface. The Companyâs development product is focused on treatment of chronic Dry Eye Disease (DED) in post-menopausal women. It is based on a naturally occurring, endogenous molecule found in the body.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
REDWOOD PHARMA AB	-83.57%	194K
MERCK KGAA	+15.54%	78.51B
KYOWA KIRIN CO. LTD.	+12.05%	9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.17%	4.96B
SK BIOPHARMACEUTICALS CO., LTD.	-14.94%	4.84B
YUHAN CORPORATION	-.--%	3.72B
INDIVIOR PLC	+21.94%	2.48B
BETTA PHARMACEUTICALS CO., LTD.	-26.63%	2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.75%	2.12B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-37.97%	1.94B